{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:07:32Z","timestamp":1794276452389,"version":"4.9.0"},"reference-count":98,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:00:00Z","timestamp":1728000000000},"content-version":"unspecified","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014820","name":"Li Ka Shing Faculty of Medicine, University of Hong Kong","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014820","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["egastro"],"accepted":{"date-parts":[[2024,9,13]]},"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as the most prevalent cause of chronic liver disease worldwide affecting over one-third of the adult population. Despite the recent evolution of new nomenclature and diagnostic criteria for MASLD, progress in drug development for this condition remains limited. This review highlights the potential of drug-target Mendelian randomisation (MR), a study design that leverages human genetics and genomics, for the discovery, repositioning and safety assessment of drug targets in MASLD. We summarised key aspects of designing and appraising a drug-target MR study, discussing its inherent assumptions and considerations for instrument selection. Furthermore, we presented real-world examples from studies in MASLD which focused on opportunities and challenges in identifying novel drug targets, repositing existing drug targets, informing adjunctive treatments and addressing issues in paediatric MASLD.<\/jats:p>","DOI":"10.1136\/egastro-2024-100114","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T13:15:28Z","timestamp":1728047728000},"page":"e100114","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":17,"title":["Drug-target Mendelian randomisation applied to metabolic dysfunction-associated steatotic liver disease: opportunities and challenges"],"prefix":"10.1136","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3368-9935","authenticated-orcid":false,"given":"Shan","family":"Luo","sequence":"first","affiliation":[{"name":"School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4984-2631","authenticated-orcid":false,"given":"Ming-Hua","family":"Zheng","sequence":"additional","affiliation":[{"name":"MAFLD Research Center, Department of Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China"},{"name":"Key Laboratory of Diagnosis and Treatment for The Development of Chronic Liver Disease, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent Wai-Sun","family":"Wong","sequence":"additional","affiliation":[{"name":"Medical Data Analytics Center, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China"},{"name":"State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6136-1836","authenticated-orcid":false,"given":"Shiu Lun","family":"Au Yeung","sequence":"additional","affiliation":[{"name":"School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,10,4]]},"reference":[{"key":"2025081719121152000_2.4.e100114.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.03.017"},{"key":"2025081719121152000_2.4.e100114.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2024.02.007"},{"key":"2025081719121152000_2.4.e100114.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.06.003"},{"key":"2025081719121152000_2.4.e100114.4","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S2468-1253(16)30011-5","article-title":"Pathogenesis and novel treatment options for non-alcoholic steatohepatitis","volume":"1","author":"Wong","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025081719121152000_2.4.e100114.5","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwm324"},{"key":"2025081719121152000_2.4.e100114.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309000"},{"key":"2025081719121152000_2.4.e100114.7","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41586-024-07316-0","article-title":"Refining the impact of genetic evidence on clinical success","volume":"629","author":"Minikel","year":"2024","journal-title":"Nat New Biol"},{"key":"2025081719121152000_2.4.e100114.8","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s41586-023-06388-8","article-title":"From target discovery to clinical drug development with human genetics","volume":"620","author":"Trajanoska","year":"2023","journal-title":"Nat New Biol"},{"key":"2025081719121152000_2.4.e100114.9","doi-asserted-by":"crossref","DOI":"10.1038\/s43586-021-00092-5","article-title":"Mendelian randomization","volume":"2","author":"Sanderson","year":"2022","journal-title":"Nat Rev Methods Primers"},{"key":"2025081719121152000_2.4.e100114.10","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad736"},{"key":"2025081719121152000_2.4.e100114.11","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-022-02246-y","article-title":"Systematic review of Mendelian randomization studies on risk of cancer","volume":"20","author":"Markozannes","year":"2022","journal-title":"BMC Med"},{"key":"2025081719121152000_2.4.e100114.12","article-title":"Mendelian Randomization Applied to Neurology: promises and Challenges","volume":"102","author":"Gagnon","year":"2024","journal-title":"Neurol (ECronicon)"},{"key":"2025081719121152000_2.4.e100114.13","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyac076"},{"key":"2025081719121152000_2.4.e100114.14","doi-asserted-by":"crossref","unstructured":"Song Y , Ye T , Roberts LR , et al . Mendelian randomization in hepatology: a review of principles, opportunities, and challenges. Hepatology 2023. doi:10.1097\/HEP.0000000000000649","DOI":"10.1097\/HEP.0000000000000649"},{"key":"2025081719121152000_2.4.e100114.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2022.12.017"},{"key":"2025081719121152000_2.4.e100114.16","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-16969-0","article-title":"Genetic drug target validation using Mendelian randomisation","volume":"11","author":"Schmidt","year":"2020","journal-title":"Nat Commun"},{"key":"2025081719121152000_2.4.e100114.17","doi-asserted-by":"crossref","unstructured":"Yuan S , Larsson SC , Gill D , et al . Concerns about instrumental variable selection for biological effect versus uptake of proton pump inhibitors in Mendelian randomisation analysis. Gut 2024. doi:10.1136\/gutjnl-2024-332280","DOI":"10.1136\/gutjnl-2024-332280"},{"key":"2025081719121152000_2.4.e100114.18","article-title":"Incorporating biological and clinical insights into variant choice for Mendelian randomisation: examples and principles","volume":"2","author":"Burgess","year":"2024","journal-title":"e Gastroenterol"},{"key":"2025081719121152000_2.4.e100114.19","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehn252"},{"key":"2025081719121152000_2.4.e100114.20","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dys221"},{"key":"2025081719121152000_2.4.e100114.21","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g4164","article-title":"Association between alcohol and cardiovascular disease: mendelian randomisation analysis based on individual participant data","volume":"349","author":"Holmes","year":"2014","journal-title":"BMJ"},{"key":"2025081719121152000_2.4.e100114.22","doi-asserted-by":"crossref","DOI":"10.1186\/s12859-022-04706-x","article-title":"An optimal variant to gene distance window derived from an empirical definition of cis and trans protein QTLs","volume":"23","author":"Fauman","year":"2022","journal-title":"BMC Bioinformatics"},{"key":"2025081719121152000_2.4.e100114.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1604304"},{"key":"2025081719121152000_2.4.e100114.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1806747"},{"key":"2025081719121152000_2.4.e100114.25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1240754","article-title":"Therapeutic role of interleukin-1 receptor antagonist in pancreatic diseases: mendelian randomization study","volume":"14","author":"Yuan","year":"2023","journal-title":"Front Immunol"},{"key":"2025081719121152000_2.4.e100114.26","doi-asserted-by":"crossref","DOI":"10.12688\/wellcomeopenres.15555.1","article-title":"Guidelines for performing Mendelian randomization investigations: update for summer 2023","volume":"4","author":"Burgess","year":"2019","journal-title":"Wellcome Open Res"},{"key":"2025081719121152000_2.4.e100114.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2022.04.001"},{"key":"2025081719121152000_2.4.e100114.28","doi-asserted-by":"publisher","DOI":"10.1002\/gepi.22506"},{"key":"2025081719121152000_2.4.e100114.29","doi-asserted-by":"publisher","DOI":"10.1038\/ng1847"},{"key":"2025081719121152000_2.4.e100114.30","doi-asserted-by":"publisher","DOI":"10.1002\/gepi.22077"},{"key":"2025081719121152000_2.4.e100114.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2023.12.002"},{"key":"2025081719121152000_2.4.e100114.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2020.04.007"},{"key":"2025081719121152000_2.4.e100114.33","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-020-00773-z"},{"key":"2025081719121152000_2.4.e100114.34","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41586-023-06592-6","article-title":"Plasma proteomic associations with genetics and health in the UK Biobank","volume":"622","author":"Sun","year":"2023","journal-title":"Nat New Biol"},{"key":"2025081719121152000_2.4.e100114.35","doi-asserted-by":"publisher","DOI":"10.1177\/0022146515594631.Marriage"},{"key":"2025081719121152000_2.4.e100114.36","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaz1776"},{"key":"2025081719121152000_2.4.e100114.37","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41586-018-0175-2","article-title":"Genomic atlas of the human plasma proteome","volume":"558","author":"Sun","year":"2018","journal-title":"Nat New Biol"},{"key":"2025081719121152000_2.4.e100114.38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3001547","article-title":"Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation","volume":"20","author":"Richardson","year":"2022","journal-title":"PLoS Biol"},{"key":"2025081719121152000_2.4.e100114.39","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104543","article-title":"Genetic association of lipids and lipid-lowering drug target genes with non-alcoholic fatty liver disease","volume":"90","author":"Li","year":"2023","journal-title":"EBioMedicine"},{"key":"2025081719121152000_2.4.e100114.40","doi-asserted-by":"crossref","first-page":"e337","DOI":"10.1016\/S2666-7568(23)00085-5","article-title":"Effects of putative metformin targets on phenotypic age and leukocyte telomere length: a mendelian randomisation study using data from the UK Biobank","volume":"4","author":"Luo","year":"2023","journal-title":"Lancet Healthy Longev"},{"key":"2025081719121152000_2.4.e100114.41","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.038814"},{"key":"2025081719121152000_2.4.e100114.42","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s00125-023-05925-4","article-title":"Genetically proxied glucose-lowering drug target perturbation and risk of cancer: a Mendelian randomisation analysis","volume":"66","author":"Yarmolinsky","year":"2023","journal-title":"Diabetologia"},{"key":"2025081719121152000_2.4.e100114.43","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.020331","article-title":"Genetic Evidence for Repurposing of GLP1R (Glucagon-Like Peptide-1 Receptor) Agonists to Prevent Heart Failure","volume":"10","author":"Daghlas","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2025081719121152000_2.4.e100114.44","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32728"},{"key":"2025081719121152000_2.4.e100114.45","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s10654-022-00868-3","article-title":"Lifestyle and metabolic factors for nonalcoholic fatty liver disease: Mendelian randomization study","volume":"37","author":"Yuan","year":"2022","journal-title":"Eur J Epidemiol"},{"key":"2025081719121152000_2.4.e100114.46","article-title":"Large-scale metabolomic profiling and incident non-alcoholic fatty liver disease","volume":"26","author":"Gagnon","year":"2023","journal-title":"i Sci"},{"key":"2025081719121152000_2.4.e100114.47","doi-asserted-by":"crossref","DOI":"10.1093\/ehjopen\/oeae035","article-title":"Drug-target Mendelian randomization analysis supports lowering plasma ANGPTL3, ANGPTL4, and APOC3 levels as strategies for reducing cardiovascular disease risk","volume":"4","author":"Landfors","year":"2024","journal-title":"Eur Heart J Open"},{"key":"2025081719121152000_2.4.e100114.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2020.11.005"},{"key":"2025081719121152000_2.4.e100114.49","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa972"},{"key":"2025081719121152000_2.4.e100114.50","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1038\/s41591-023-02494-2","article-title":"RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts","volume":"29","author":"Watts","year":"2023","journal-title":"N Med"},{"key":"2025081719121152000_2.4.e100114.51","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612790"},{"key":"2025081719121152000_2.4.e100114.52","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa689"},{"key":"2025081719121152000_2.4.e100114.53","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004215"},{"key":"2025081719121152000_2.4.e100114.54","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.031335"},{"key":"2025081719121152000_2.4.e100114.55","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.123.065866"},{"key":"2025081719121152000_2.4.e100114.56","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/eurheartj\/ehad845","article-title":"Genetic inhibition of angiopoietin-like protein-3, lipids, and cardiometabolic risk","volume":"45","author":"Gobeil","year":"2024","journal-title":"Eur Heart J"},{"key":"2025081719121152000_2.4.e100114.57","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41586-020-2267-z","article-title":"Evaluating drug targets through human loss-of-function genetic variation","volume":"581","author":"Minikel","year":"2020","journal-title":"Nat New Biol"},{"key":"2025081719121152000_2.4.e100114.58","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-03911-8","article-title":"Analysis of predicted loss-of-function variants in UK Biobank identifies variants protective for disease","volume":"9","author":"Emdin","year":"2018","journal-title":"Nat Commun"},{"key":"2025081719121152000_2.4.e100114.59","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-03910-9","article-title":"Medical relevance of protein-truncating variants across 337,205 individuals in the UK Biobank study","volume":"9","author":"DeBoever","year":"2018","journal-title":"Nat Commun"},{"key":"2025081719121152000_2.4.e100114.60","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/hep.29897","article-title":"Nonalcoholic fatty liver disease: is it time for combination treatment and a diabetes-like approach?","volume":"68","author":"Polyzos","year":"2018","journal-title":"Hepatology"},{"key":"2025081719121152000_2.4.e100114.61","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/ije\/dyz161","article-title":"Factorial Mendelian randomization: using genetic variants to assess interactions","volume":"49","author":"Rees","year":"2020","journal-title":"Int J Epidemiol"},{"key":"2025081719121152000_2.4.e100114.62","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.0305","article-title":"Combined Association of Body Mass Index and Alcohol Consumption With Biomarkers for Liver Injury and Incidence of Liver Disease: a Mendelian Randomization Study","volume":"2","author":"Carter","year":"2019","journal-title":"JAMA Netw Open"},{"key":"2025081719121152000_2.4.e100114.63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.02.020"},{"key":"2025081719121152000_2.4.e100114.64","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1001\/jamacardio.2022.2333","article-title":"Joint Genetic Inhibition of PCSK9 and CETP and the Association With Coronary Artery Disease: a Factorial Mendelian Randomization Study","volume":"7","author":"Cupido","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2025081719121152000_2.4.e100114.65","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.023277","article-title":"Additive Effects of Genetic Interleukin-6 Signaling Downregulation and Low-Density Lipoprotein Cholesterol Lowering on Cardiovascular Disease: A 2\u00d72 Factorial Mendelian Randomization Analysis","volume":"11","author":"Georgakis","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2025081719121152000_2.4.e100114.66","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd5524","article-title":"Drug repurposing: misconceptions, challenges, and opportunities for academic researchers","volume":"13","author":"Begley","year":"2021","journal-title":"Sci Transl Med"},{"key":"2025081719121152000_2.4.e100114.67","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/s41591-021-01310-z","article-title":"Actionable druggable genome-wide Mendelian randomization identifies repurposing opportunities for COVID-19","volume":"27","author":"Gaziano","year":"2021","journal-title":"N Med"},{"key":"2025081719121152000_2.4.e100114.68","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30345-3"},{"key":"2025081719121152000_2.4.e100114.69","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.03545-2020","article-title":"Genetically proxied interleukin-6 receptor inhibition: opposing associations with COVID-19 and pneumonia","volume":"57","author":"Larsson","year":"2021","journal-title":"Eur Respir J"},{"key":"2025081719121152000_2.4.e100114.70","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1056\/NEJMc2108482","article-title":"Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19","volume":"385","author":"Brown","year":"2021","journal-title":"N Engl J Med"},{"key":"2025081719121152000_2.4.e100114.71","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0165"},{"key":"2025081719121152000_2.4.e100114.72","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00261-2"},{"key":"2025081719121152000_2.4.e100114.73","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028395"},{"key":"2025081719121152000_2.4.e100114.74","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.01.051"},{"key":"2025081719121152000_2.4.e100114.75","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","article-title":"SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control","volume":"17","author":"Cowie","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"2025081719121152000_2.4.e100114.76","doi-asserted-by":"crossref","DOI":"10.3390\/genes12081174","article-title":"Search for a Functional Genetic Variant Mimicking the Effect of SGLT2 Inhibitor Treatment","volume":"12","author":"Wang","year":"2021","journal-title":"Genes (Basel)"},{"key":"2025081719121152000_2.4.e100114.77","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1093\/cvr\/cvad122","article-title":"Genetic variation in solute carrier family 5 member 2 mimicking sodium-glucose co-transporter 2-inhibition and risk of cardiovascular disease and all-cause mortality: reduced risk not explained by lower plasma glucose","volume":"119","author":"Bechmann","year":"2023","journal-title":"Cardiovasc Res"},{"key":"2025081719121152000_2.4.e100114.78","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1097\/HEP.0000000000000837","article-title":"Inhibition of sodium-glucose cotransporter-2 and liver-related complications in individuals with diabetes: a Mendelian randomization and population-based cohort study","volume":"80","author":"Chung","year":"2024","journal-title":"Hepatology"},{"key":"2025081719121152000_2.4.e100114.79","doi-asserted-by":"crossref","DOI":"10.1038\/s42003-024-05977-1","article-title":"A two-sample Mendelian randomization study explores metabolic profiling of different glycemic traits","volume":"7","author":"Wong","year":"2024","journal-title":"Commun Biol"},{"key":"2025081719121152000_2.4.e100114.80","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1001\/jama.2024.1215","article-title":"Aspirin for Metabolic Dysfunction-Associated Steatotic Liver Disease Without Cirrhosis: a Randomized Clinical Trial","volume":"331","author":"Simon","year":"2024","journal-title":"JAMA"},{"key":"2025081719121152000_2.4.e100114.81","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(03)00379-7"},{"key":"2025081719121152000_2.4.e100114.82","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1007\/s00125-023-05875-x","article-title":"Drug target Mendelian randomisation: are we really instrumenting drug use?","volume":"66","author":"Anderson","year":"2023","journal-title":"Diabetologia"},{"key":"2025081719121152000_2.4.e100114.83","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-023-00833-4"},{"key":"2025081719121152000_2.4.e100114.84","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183"},{"key":"2025081719121152000_2.4.e100114.85","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/gepi.22551","article-title":"Robust use of phenotypic heterogeneity at drug target genes for mechanistic insights: application of cis-multivariable Mendelian randomization to GLP1R gene region","volume":"48","author":"Patel","year":"2024","journal-title":"Genet Epidemiol"},{"key":"2025081719121152000_2.4.e100114.86","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1097\/HEP.0000000000000383","article-title":"Global and national prevalence of nonalcoholic fatty liver disease in adolescents: an analysis of the global burden of disease study 2019","volume":"78","author":"Hartmann","year":"2023","journal-title":"Hepatology"},{"key":"2025081719121152000_2.4.e100114.87","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2011.01.016"},{"key":"2025081719121152000_2.4.e100114.88","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.520"},{"key":"2025081719121152000_2.4.e100114.89","doi-asserted-by":"crossref","first-page":"4795","DOI":"10.1007\/s00431-023-05169-9","article-title":"The benefit of metformin in the treatment of pediatric non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials","volume":"182","author":"Gkiourtzis","year":"2023","journal-title":"Eur J Pediatr"},{"key":"2025081719121152000_2.4.e100114.90","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/S2468-1253(21)00183-7","article-title":"Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement","volume":"6","author":"Eslam","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025081719121152000_2.4.e100114.91","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.medj.2024.03.017","article-title":"An international multidisciplinary consensus on pediatric metabolic dysfunction-associated fatty liver disease","volume":"5","author":"Zhang","year":"2024","journal-title":"Med"},{"key":"2025081719121152000_2.4.e100114.92","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1016\/j.jhep.2024.03.042","article-title":"The MASLD criteria overlook a number of adolescent patients with severe steatosis","volume":"81","author":"Pan","year":"2024","journal-title":"J Hepatol"},{"key":"2025081719121152000_2.4.e100114.93","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1053\/j.gastro.2020.01.048","article-title":"Nonalcoholic Fatty Liver Disease in Children: unique Considerations and Challenges","volume":"158","author":"Goldner","year":"2020","journal-title":"Gastroenterology"},{"key":"2025081719121152000_2.4.e100114.94","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-023-03115-y","article-title":"Assessing the safety of lipid-modifying medications among Chinese adolescents: a drug-target Mendelian randomization study","volume":"21","author":"Luo","year":"2023","journal-title":"BMC Med"},{"key":"2025081719121152000_2.4.e100114.95","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-022-02483-1","article-title":"Safety of beta-blocker and calcium channel blocker antihypertensive drugs in pregnancy: a Mendelian randomization study","volume":"20","author":"Ardissino","year":"2022","journal-title":"BMC Med"},{"key":"2025081719121152000_2.4.e100114.96","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.05.025"},{"key":"2025081719121152000_2.4.e100114.97","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-022-01199-5"},{"key":"2025081719121152000_2.4.e100114.98","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.04.003"}],"container-title":["eGastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/egastro-2024-100114","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T02:17:32Z","timestamp":1755483452000},"score":1,"resource":{"primary":{"URL":"http:\/\/egastroenterology.bmj.com\/lookup\/doi\/10.1136\/egastro-2024-100114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":98,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,10,4]]},"published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1136\/egastro-2024-100114"],"URL":"https:\/\/doi.org\/10.1136\/egastro-2024-100114","relation":{},"ISSN":["2766-0125","2976-7296"],"issn-type":[{"value":"2766-0125","type":"print"},{"value":"2976-7296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10]]}}}